Common use of Screening Programs Clause in Contracts

Screening Programs. Within thirty (30) days after the Effective Date, SPL shall notify Pharmacopeia in writing of the identity of*Screening Targets. Such notice shall include the applicable Activity Criteria recommended by SPL for each proposed Screening Target, which Activity Criteria shall constitute Schering Know-How. Such Activity Criteria shall include, without limitation, *Pharmacopeia shall have the right to reject any proposed Targets as Screening Targets if: (i) it has a pre-existing contractual obligation to any Third Party that provides for exclusivity and/or non-compete obligations with respect to such Target; or (ii) Pharmacopeia has previously screened one or more Pharmacopeia Compounds against the same Target and there are less than two million (2,000,000) Pharmacopeia Compounds that have not previously been screened against the Target; or (iii) in accordance with the terms of Section 2.12. In addition, in the event that Pharmacopeia reasonably believes (based upon objective scientific information) that the Activity Criteria recommended by SPL for a proposed Screening Target are not reasonably attainable, then the Collaboration Committee shall promptly meet to agree in good faith upon mutually acceptable Activity Criteria. Pharmacopeia shall promptly notify in writing whether it accepts or rejects each such Target as a Screening Target. SPL shall have the right to propose a replacement Target for each Target rejected by Pharmacopeia, which replacement Target may be accepted or rejected by Pharmacopeia, as described above. The Parties shall use reasonable efforts to agree on *SPL shall propose*additional Targets for acceptance by Pharmacopeia as Screening Targets for Screening Programs. Pharmacopeia shall have the right to accept or reject such Targets, as described above, and the Parties shall use reasonable efforts to agree on *new Screening Targets for Screening Programs to be conducted by Pharmacopeia *To the extent that SPL will be funding *the Parties shall use reasonable efforts to agree upon *new Targets (to be proposed by SPL *as Screening Targets for Screening Programs to be conducted by Pharmacopeia *

Appears in 3 contracts

Samples: Collaboration and License Agreement, Collaboration and License Agreement (Ligand Pharmaceuticals Inc), Collaboration and License Agreement (Pharmacopeia Inc)

AutoNDA by SimpleDocs

Screening Programs. Within thirty (30) days after the Effective Date, SPL Schering shall notify Pharmacopeia in writing of the identity of*Screening of * Screening Targets. Such notice shall include the applicable Activity Criteria recommended by SPL Schering for each proposed Screening Target, which Activity Criteria shall constitute Schering Know-How. Such Activity Criteria shall include, without limitation, ** Pharmacopeia shall have the right to reject any proposed Targets as Screening Targets if: (i) it has a pre-existing contractual obligation to any Third Party that provides for exclusivity and/or non-compete obligations with respect to such Target; or (ii) Pharmacopeia has previously screened one or more Pharmacopeia Compounds against the same Target and there are less than two million (2,000,000) Pharmacopeia Compounds that have not previously been screened against the Target; or (iii) in accordance with the terms of Section 2.12. In addition, in the event that Pharmacopeia reasonably believes (based upon objective scientific information) that the Activity Criteria recommended by SPL Schering for a proposed Screening Target are not reasonably attainable, then the Collaboration Committee shall promptly meet to agree in good faith upon mutually acceptable Activity Criteria. Pharmacopeia shall promptly notify in writing whether it accepts or rejects each such Target as a Screening Target. SPL Schering shall have the right to propose a replacement Target for each Target rejected by Pharmacopeia, which replacement Target may be accepted or rejected by Pharmacopeia, as described above. The Parties shall use reasonable efforts to agree on *SPL * Schering shall propose*additional propose * additional Targets for acceptance by Pharmacopeia as Screening Targets for Screening Programs. Pharmacopeia shall have the right to accept or reject such Targets, as described above, and the Parties shall use reasonable efforts to agree on ** new Screening Targets for Screening Programs to be conducted by Pharmacopeia ** To the extent that SPL Schering will be funding ** the Parties shall use reasonable efforts to agree upon ** new Targets (to be proposed by SPL *Schering * as Screening Targets for Screening Programs to be conducted by Pharmacopeia *

Appears in 2 contracts

Samples: Collaboration and License Agreement (Ligand Pharmaceuticals Inc), Collaboration and License Agreement (Pharmacopeia Inc)

AutoNDA by SimpleDocs
Time is Money Join Law Insider Premium to draft better contracts faster.